Biogen profit rises 3.2% on demand for multiple sclerosis drug By Reuters

0
22
© Reuters. FILE PHOTO: A Biogen sign at the company


© Reuters. FILE PHOTO: A Biogen sign at the company’s facility in Cambridge, Massachusetts

(Reuters) – Biogen Inc (NASDAQ:) reported a 3.2% rise in second-quarter profit on Wednesday, getting a lift from demand for its top-selling multiple sclerosis drug Tecfidera.

Net income attributable to the company rose to $1.54 billion, or $9.59 per share, in the three months ended June 30 from $1.49 billion, or $7.85 per share, a year earlier. (https://

Total revenue rose to $3.68 billion from $3.62 billion.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here